Dirk Thye, Quince Therapeutics CEO
After pivoting from Alzheimer's to bone conditions, biotech pivots again — and halves its headcount
When troubled public biotech Cortexyme bought a private startup named Novosteo and handed the keys to its executive team, the company — which changed its name …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.